Case 06-12

After having a very successful performance and getting second place on the first Littlefield simulation game we knew what we needed to do to win the second simulation game. We were very eager to outperform our competition and we almost did so, but ended up in second place again with a cash balance of $2,660,393.

2. Is there evidence of disparate impact against African Americans in the decisions that were made? On what basis did you arrive at this position? Illustrate how the “80 percent rule” can be used with the data in Exhibit 3.2.1 and whether there was a violation of this rule.

This memo is intend to present appropriate treatment of the ARO estimation problem experienced by the Lack of Information (LOI) based on the findings from interviews with all 50 of the warehouse managers and on-site visits at each of the 50 locations of its warehouses countrywide. The onsite observations search for any evidence of damages in both the on-site property like the roof, walls, floors and general conditions. The interview with the managers obtains information about the characteristics of the warehouses that are not readily observable. The information obtained is very important in the preparation of the fiscal

Based on our learning from week one of our class, the purpose of this paper is to discuss the leadership perspectives manifested in both Bobby Knight and Mike Krzyzewski, coaches who have made significant marks in their field in college basketball. I hope to be able to identify the power bases both coaches rely upon, as well as whether their actions are more aligned with either a managerial role or leadership role. In addition, I hope to identify how significant the leadership traits have influenced their leadership, based on the five-factor

2. List the questions raised about this situation or that you think that the investigators should ask of the

The report analyzes three options to record the transfer of the in process research and development project Drug X from Bust-a-Knee to Pharmers. Based on the analysis, we recommend Options #3 as the approach to record the journal entries at the date of transfer.

Unfortunately if you read ASC 730-20-25-8 describing what constitutes an obligation to perform contractual services, it “depends solely on the results of the research and development having future economic benefit.” Since part of the agreement entails payment of royalties from an existing commercialized drug, Pharmagen is not transferring all the financial risk because the repayment is not exclusively reliant on the development of the new drug X. This is why I believe it is the best practice to record the funding as a liability and according to ASC 730-20-25-7, “charge the research and development costs to expense as incurred.”

At 14:32 Haring was arrested for OWI and fleeing the scene of an accident. He was taken away for booking and a Data Master Breathalyzer test.

In the short-term, the milestone payments represent a known and assured series of cash inflows to Raisio for its intellectual property. Raisio incurs no direct expenses related to these payments; they are simply returns on the intellectual property held by Raisio, and in which it has invested years of capital and intellectual resources to create. On a continuing basis, as Benecol gains wider and wider acceptance and distribution, Raisio would continue to provide all of the stanol estor Benecol’s key chemical ingredient manufactured by Raisio alone assuring a continuing sale at an acceptable transfer price. Note that this is more consistent with Raisio’s traditional core competencies, the manufacturing of industrial chemicals. (By the way, students may be surprised to find that margarine is generally regarded as a chemical product.) Over the life of the agreement Raisio would receive a royalty payment calculated as a percentage of the final retail product price of any product containing Benecol. This is a very attractive element of the agreement to a company like Raisio, as it in no way requires Raisio to be involved or concerned with the variety of different products or ways in which it may finally be distributed. As such, it simply reaps an income stream on the basis of sales, not profitability.

An act to amend Virginia code 20-124 paragraph two, point three and subsection F of 63.2-1202 in regards to subsection A of 18.2-61 to apply not only to convicted persons but also to an accused person when there is clear and convincing evidence of rape (Definitions; Megison; Rape; Parental, or agency, consent required; exceptions).

Pharmagen entered into a funding agreement with Company XYZ, an unrelated third-party private equity investor (PEI)

2. What would have been Martin’s return for years 2000, 2001, and 2002 if his portfolio had remained with its initial holdings?

If either Sepsis or Diabetes deal come through, the firm will be at an excellent position, with an assured firm value of $25 million and a complete control of the company for the owners. In terms of choosing between the two deals, the Sepsis deal is more fruitful as we receive $5 million up-front and $108 million milestone payments after the drug passes the phase 2 test in the Sepsis. In contrast, the Diabetes deal fetches $8 million up-front and $80 million milestone payment which is too less. In addition, the potential sales for Sepsis are $0.5 billion annually compared to $4 billion for diabetes. It is not a smart decision if we give up large portion of future proceeds from selling Diabetes drugs. Purinex only needs small cash to cover its general operating and R&D research costs; $5 million up-front payment from sepsis partner is enough for next 83 months.

Having estimated gross sales (Table 4) up to the year 2002, we can estimate revenues for each option for phase III. Although Nucleon in initial has to invest huge amount of money for plant facility and development resources for commercial manufacturing, however, it can give Nucleon a significant revenues compare to licensing.

This way they could tell if shareholder wealth would be created. There is a risk due to the cost of equity since it is more complex and is assumed to be the amount that an investor could earn. My advice to Elaine would not change due to the fact that the patent is needed and could create something good for the pharmaceutical industry. She should explain that there was a difference in the ROI but costs are necessary in creating the patent.